Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the efficacy and safety of lixisenatide (20 μg once daily, administered before the morning or evening meal) as add-on therapy in patients with type 2 diabetes insufficiently controlled with metformin alone. RESEARCH DESIGN AND METHODS: This was a 24-week, randomized, double-blind, placebo-controlled study in 680 patients with inadequately controlled type 2 diabetes (HbA1c 7–10% [53−86 mmol/mol]). Patients were randomized to lixisenatide morning (n = 255), lixisenatide evening (n = 255), placebo morning (n = 85), or placebo evening (n = 85) injections. RESULTS: Lixisenatide morning injection significantly reduced mean HbA1c versus combined placebo (mean change −0.9% [9.8 mmol/mol] vs. −0.4% [4.4 mmol/mol]; least squares [LS] mean difference vs. placebo −0.5% [5.5 mmol/mol], P < 0.0001). HbA1c was significantly reduced by lixisenatide evening injection (mean change –0.8% [8.7 mmol/mol] vs. –0.4% [4.4 mmol/mol]; LS mean difference –0.4% [4.4 mmol/mol], P < 0.0001). Lixisenatide morning injection significantly reduced 2-h postprandial glucose versus morning placebo (mean change −5.9 vs. −1.4 mmol/L; LS mean difference −4.5 mmol/L, P < 0.0001). LS mean difference in fasting plasma glucose was significant in both morning (–0.9 mmol/L, P < 0.0001) and evening (–0.6 mmol/L, P = 0.0046) groups versus placebo. Mean body weight decreased to a similar extent in all groups. Rates of adverse events were 69.4% in both lixisenatide groups and 60.0% in the placebo group. Rates for nausea and vomiting were 22.7 and 9.4% for lixisenatide morning and 21.2 and 13.3% for lixisenatide evening versus 7.6 and 2.9% for placebo, respectively. Symptomatic hypoglycemia occurred in 6, 13, and 1 patient for lixisenatide morning, evening, and placebo, respectively, with no severe episodes. CONCLUSIONS: In patients with type 2 diabetes inadequately controlled on metformin, lixisenatide 20 μg once daily administered in the morning or evening significantly improved glycemic control, with a pronounced postprandial effect, and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 LS mean change in postprandial glucose (A) and glucose excursion (B) from baseline to week 24 (last observation carried forward [LOCF]) with lixisenatide morning and placebo morning once-daily regimens. Data are mean values for the mITT population. Error bars represent the standard error. Glucose excursion calculated as 2-h PPG minus plasma glucose 30 min prior to the meal before study drug administration.](https://figures.cochat.ai/paper-figures/6c4743ce03ec4ab4812ca9679c66de5c/efficacy-and-safety-of-lixisenatide-once-daily-morning-or-evening-injections-in-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Once daily lixisenatide, structurally similar to exenatide and administered by subcutaneous injection, was later approved and found to reduce HbA1c by 0.8–0.9%.14”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“7 mmol/mol [66 to 57 mmol/mol]) using the highest dose of 10 mg twice daily (10).”
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261
Seino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Self-citationEfficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Self-citation
Cited by
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“[186] , and in another 24-wk no inferiority trial of once-daily subcutaneous lixisenatide 20 mcg once daily vs exenatide 10 mcg twice daily in 634 T2DM patients inadequately controlled with metformin alone (mean baseline HbA1c 8%), lixisenatide was no inferior to exenatide (mean change HbA1c -0.79%…”
BackgroundInfluentialFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy
Dallmann, R., Okyar, A., & Lévi, F. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.004 · Cited by 293
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Insulin resistance and insulin sensitizing agents
Mastrototaro, L., & Roden, M. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154892 · Cited by 254
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Self-citationGLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
“events of LIXI are gastrointestinal adverse reactions, mainly manifested as nausea and vomiting in the initial stage (75, 76).”
BackgroundRuben, M. D., Smith, D. F., FitzGerald, G. A., & Hogenesch, J. B. (2019) · Science · doi:10.1126/science.aax7621 · Cited by 236
Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 227
“6 kg from baseline have been reported in patients treated with GLP‐1 RAs when added to metformin.(11,18,19,23,31,37,42,47,51,59) Changes in body weight for long‐acting agents (some administered in combination with other OADs) in key clinical trials ranged from +0.”
BackgroundAlfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
Battle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
Weinstock, R. S., Guerci, B., Umpierrez, G., Nauck, M. A., Skrivanek, Z., & Milicevic, Z. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12479 · Cited by 149
GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
del Olmo-Garcia, M. I., & Merino-Torres, J. F. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4020492 · Cited by 138
Lund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 164
Lorenz, M., Pfeiffer, C., Steinsträßer, A., Becker, R. H. A., Rütten, H., Ruus, P., & Horowitz, M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.04.001 · Cited by 149
Pinget, M., Goldenberg, R., Niemoeller, E., Muehlen‐Bartmer, I., Guo, H., & Aronson, R. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12121 · Cited by 139
“The results of this study are consistent with, and extend the results of, previously reported phase III studies of lixisenatide in patients with T2DM, either untreated [14] or inadequately controlled on metformin alone [13,15,21], on sulphonylurea therapy with or without metformin [9], and on basal insulin plus oral a…”
ResultSelf-citationBrunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130
Rosenstock, J., Hanefeld, M., Shamanna, P., Min, K. W., Boka, G., Miossec, P., Zhou, T., Muehlen-Bartmer, I., & Ratner, R. E. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.012 · Cited by 130
Self-citationHu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127
“, 2013 (49) NCT00712673 76 Lixisenatide Placebo 1/510 1/170 54.”
Kapitza, C., Dahl, K., Jacobsen, J. B., Axelsen, M. B., & Flint, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4289-0 · Cited by 117
“GLP-1RAs help to restore beta cell sensitivity to elevated blood glucose and improve beta cell function across a number of indices in people with type 2 diabetes [5, 6].”
BackgroundScott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancáková, A., Chen, Y., Varga, T. V., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3744 · Cited by 118
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Chiang, C.-H., Jaroenlapnopparat, A., Colak, S. C., Yu, C.-C., Xanthavanij, N., Wang, T.-H., See, X. Y., Lo, S.-W., Ko, A., Chang, Y.-C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.003 · Cited by 105
Cao, C., Yang, S., & Zhou, Z. (2019) · Endocrine · doi:10.1007/s12020-019-02055-z · Cited by 99
GLP‐1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents
Trujillo, J. M., & Nuffer, W. (2014) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1507 · Cited by 95
Giorda, C. B., Nada, E., & Tartaglino, B. (2014) · Endocrine · doi:10.1007/s12020-014-0179-0 · Cited by 89
“With regard to the effects of GLP-1 receptor agonists, there are no data from clinical trials on the efficacy of exenatide and lixisenatide in patients with renal impairment [59].”
BackgroundRosenstock, J., Diamant, M., Aroda, V. R., Silvestre, L., Souhami, E., Zhou, T., Perfetti, R., Fonseca, V., & for the LixiLan PoC Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0046 · Cited by 86
Tang, H., Li, G., Zhao, Y., Wang, F., Gower, E. W., Shi, L., & Wang, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13232 · Cited by 78
Novel agents for the treatment of type 2 diabetes
DeFronzo, R. A., Triplitt, C. L., Abdul-Ghani, M., & Cersosimo, E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.100 · Cited by 83
Owens, D., Monnier, L., & Bolli, G. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.004 · Cited by 82
Monnier, L., & Colette, C. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30003-9 · Cited by 78
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 79
Adetunji, O., Kalra, S., Baruah, M., Sahay, R., Unnikrishnan, A., & Uppal, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.176351 · Cited by 71
Yu Pan, C., Han, P., Liu, X., Yan, S., Feng, P., Zhou, Z., Lv, X., Tian, H., Jin Kui, Y., Su, B., et al. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2541 · Cited by 71
“6% with placebo) [21] or GetGoal-S (25.”
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Lovshin, J. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.242 · Cited by 74
Potential side effects to GLP-1 agonists: understanding their safety and tolerability
Consoli, A., & Formoso, G. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.987122 · Cited by 63
“1 [36,42,49,100-104] Liraglutide 20 8 11 -- 14 5 -- 9 [68] 10.”
Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease
Hershon, K. S., Hirsch, B. R., & Odugbesan, O. (2019) · Clinical Diabetes · doi:10.2337/cd18-0040 · Cited by 67
Pharmacological treatment of diabetes in older people
Valencia, W. M., & Florez, H. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12362 · Cited by 62
“Safety and glycaemic control efficacy data have been reported with lixisenatide as monotherapy [76] or as add-on therapy to metformin [77], with both therapeutic strategies reported as having a pronounced postprandial effect and being well tolerated.”
BackgroundGluud, L. L., Knop, F. K., & Vilsbøll, T. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005325 · Cited by 59
Xie, X., Yang, S., Deng, S., Liu, Y., Xu, Z., & He, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613610 · Cited by 57
Kramer, C. K., Zinman, B., Choi, H., Connelly, P. W., & Retnakaran, R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2725 · Cited by 54
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Tella, S. H., & Rendell, M. S. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815580257 · Cited by 46
Owens, D. R., Monnier, L., & Barnett, A. H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12977 · Cited by 57
Raccah, D., Miossec, P., Esposito, V., Niemoeller, E., Cho, M., & Gerich, J. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2588 · Cited by 50
“12-week randomized controlled trial NCT00712673 GetGoal-M [25] Lixisenatide versus placebo added to existing MET.”
BackgroundSelf-citationCircadian Variation in Efficacy of Medications
Walton, J. C., Walker, W. H., Bumgarner, J. R., Meléndez‐Fernández, O. H., Liu, J. A., Hughes, H. L., Kaper, A. L., & Nelson, R. J. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2073 · Cited by 55
“In patients with T2DM who experience inadequate control of glucose levels by metformin, a double-blind placebo-controlled trial in 680 patients reported that morning and evening lixisenatide injections similarly improve glucose control.(104) Repaglinide, a fast-acting meglitinide, was also reported to be more Drug cla…”
BackgroundKo, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02237 · Cited by 57
Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
Becker, R. H. A., Stechl, J., Steinstraesser, A., Golor, G., & Pellissier, F. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2647 · Cited by 49
Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
Charbonnel, B., Bertolini, M., Tinahones, F. J., Domingo, M. P., & Davies, M. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.07.007 · Cited by 48
Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244432 · Cited by 47
Werner, U. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.06.003 · Cited by 47
“…efficacy of lixisenatide versus placebo in reducing glycated hemoglobin (HbA1c); there is particular efficacy of this agent on PPG excursions (Ahrén et al., 2013; Bolli et al., 2011; Fonseca et al., 2012; Pinget et al., 2013; Ratner et al., 2011; Riddle et al., 2013b; Rosenstock et al.,…”
BackgroundWitkowski, M., Wilkinson, L., Webb, N., Weids, A., Glah, D., & Vrazic, H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0424-2 · Cited by 45
NIRANJAN, S., Phillips, B. E., & Giannoukakis, N. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1193373 · Cited by 51
“GLP-1 agonists like exenatide, liraglutide, semaglutide, and lixisenide can improve insulin sensitivity, although it is not clear if this effect is in the periphery or in the liver as well (94, 96, 102, 127, 128).”
BackgroundKayaniyil, S., Lozano-Ortega, G., Bennett, H. A., Johnsson, K., Shaunik, A., Grandy, S., & Kartman, B. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0155-1 · Cited by 43
“Only two studies [25, 38] noted differences in gender proportions at baseline between treatment groups, but significance was not tested.”
Palanisamy, S., Yien, E. L. H., Shi, L., Yi, L., Qi, S. H., Soon, L., Lun, T. W., & Chen, Y. N. (2018) · Pharmacy · doi:10.3390/pharmacy6030057 · Cited by 48
“This is aligned with the GetGoal-M study results of achieving significant improvement in glycemic control after 24-week treatment of lixisenatide added to metformin, regardless of morning or evening meal administration [81].”
Nuhoho, S., Gupta, J., Hansen, B. B., Fletcher-Louis, M., Dang-Tan, T., & Paine, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00706-y · Cited by 41
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
Petersen, B., & Christensen (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s45379 · Cited by 42
“Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013:6 placebo (Table 3).(51,58,59) Furthermore, no severe hypoglycemic events were reported in any of these studies.”
Meneilly, G. S., Roy-Duval, C., Alawi, H., Dailey, G., Bellido, D., Trescoli, C., Manrique Hurtado, H., Guo, H., Pilorget, V., Perfetti, R., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2143 · Cited by 38
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121808 · Cited by 38
“The prevalence of hypoglycemia did not differ between the lixisenatide and placebo groups.[42,43] Pinget et al.”
BackgroundBolli, G. B., & Owens, D. R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12253 · Cited by 36
“Three studies (GetGoal-M [49], GetGoal-F1 [50] and GetGoalX [51]) have examined the efficacy and safety of lixisenatide once-daily as add-on therapy to metformin in adults with T2DM.”
BackgroundMethodLixisenatide in type 2 diabetes: latest evidence and clinical usefulness
Anderson, S. L., & Trujillo, J. M. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315609312 · Cited by 36
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001197 · Cited by 35
Yang, W., Min, K. W., Zhou, Z., Li, L., Xu, X., Zhu, D., Rao, A. V., Murthy, L. S., Zhang, N., Li, I., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13072 · Cited by 37
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Christensen, M., Miossec, P., Larsen, B. D., Werner, U., & Knop, F. K. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942638 · Cited by 34
“administered in the morning significantly improved 2-h PPG in patients with T2DM inadequately controlled on metformin [69].”
BackgroundSelf-citationLi, Z., Zhang, Y., Quan, X., Yang, Z., Zeng, X., Ji, L., Sun, F., & Zhan, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154206 · Cited by 33
“1 Ahren B, 2013[31] Placebo,Lixisenatide 1, 2, 3, 4 680 Met 24 54.”
Natale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., & Strippoli, G. F. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015849.pub2 · Cited by 40
Residual dysglycemia when at target HbA1c of 7% (53mmol/mol) in persons with type 2 diabetes
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.03.012 · Cited by 32
Åhrén, B., Gautier, J., Berria, R., Stager, W., Aronson, R., & Bailey, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12290 · Cited by 33
“All patients received concomitant metformin in studies GetGoal-M and GetGoal-Duo-1; basal insulin in GetGoal-L, GetGoal-Duo-1 and GetGoal-L-Asia; and sulfonylurea in GetGoal-S.”
MethodInfluentialSelf-citationDetermining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus
Khan, M. A., Ouyang, J., Perkins, K., Nair, S., & Joseph, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/162718 · Cited by 32
“To date, several clinical trials have demonstrated their efficacious ability to induce weight loss and improve glycaemic control in type 2 diabetic patients [14–24].”
BackgroundSemaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
Inia, J. A., Stokman, G., Morrison, M. C., Worms, N., Verschuren, L., Caspers, M. P. M., Menke, A. L., Petitjean, L., Chen, L., Petitjean, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108494 · Cited by 33
Schmidt, L. J., Habacher, W., Augustin, T., Krahulec, E., & Semlitsch, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12269 · Cited by 31
Wysham, C., Bonadonna, R. C., Aroda, V. R., Puig‐Domingo, M., Kapitza, C., Stager, W., Yu, C. H., Niemoeller, E., Souhami, E., Bergenstal, R. M., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12961 · Cited by 31
The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs
Rodbard, H. W. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0103 · Cited by 30
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
Bain, S. C. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0073-z · Cited by 29
Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9325-8 · Cited by 30
Małyszczak, A., Przeździecka-Dołyk, J., Szydełko-Paśko, U., & Misiuk‐Hojło, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061797 · Cited by 30
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 29
“After being approved, daily lixisenatide, which is structurally like exenatide and is administered by subcutaneous injection— was discovered to lower HbA1c by 0.8 to 0.9% [89].”
Influentialde Wit, H. M., Groen, M. T., Rovers, M. M., & Tack, C. J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12925 · Cited by 29
Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management
McCarty, D., Coleman, M., & Boland, C. L. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017689878 · Cited by 27
“Mild dysglycemia” in type 2 diabetes: to be neglected or not?
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.12.004 · Cited by 31
Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 27
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838559 · Cited by 25
“So far, nine of these trials have been published (Table 1), including the effects of lixisenatide once-daily in monotherapy [32], with oral antidiabetic agents (OADs; metformin, sulfonylureas or thiazolidinediones) [33,34], or basal insulin glargine [35-37], as well as in direct comparison with exenatide [38].”
BackgroundDar, S., Tahrani, A. A., & Piya, M. K. (2015) · Practical Diabetes · doi:10.1002/pdi.1978 · Cited by 28
Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24
Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2013) · BioDrugs · doi:10.1007/s40259-013-0057-y · Cited by 26
“94) compared with placebo in GetGoal-M [26].”
BackgroundMethodInfluentialBecker, R. H. A., Stechl, J., Msihid, J., & Kapitza, C. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12278 · Cited by 25
Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
Hanefeld, M., Arteaga, J. M., Leiter, L. A., Marchesini, G., Nikonova, E., Shestakova, M., Stager, W., & Gómez‐Huelgas, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12986 · Cited by 22
Van Gaal, L., Souhami, E., Zhou, T., & Aronson, R. (2014) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2014.03.001 · Cited by 22
Self-citationGrøndahl, M. F. G., Keating, D. J., Vilsbøll, T., & Knop, F. K. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0967-z · Cited by 23
Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.
Leon, N., LaCoursiere, R. J., Yarosh, D., & Patel, R. S. (2017) · PubMed · Cited by 35
Trujillo, J. M., & Goldman, J. D. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1962 · Cited by 22
Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day
Ahrén, B., Vorokhobina, N., Souhami, E., Demil, N., Ye, J., & Aronson, R. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.05.012 · Cited by 19
“As such, although the improved glycaemia versus placebo was similar in the two groups, direct comparisons between morning and evening lixisenatide dosing could not be drawn [10].”
BackgroundInfluentialSelf-citationTaj, S., Zuber, M., Rashid, M., Chhabra, M., Undela, K., Rawal, S., & Zapata, L. V. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70382 · Cited by 19
“28,52 These agents, therefore, appear less likely to produce significant ISR-related tolerability issues, a pattern consistent with the absence of FAERS signals in our study.”
Seino, Y., Yabe, D., Takami, A., Niemoeller, E., & Takagi, H. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.003 · Cited by 18
“Lixisenatide has been extensively evaluated in the phase III ‘GetGoal’ clinical trials program, in which it was shown to be efficacious and well tolerated in patients with T2DM (Ahren et al., 2013; Fonseca et al., 2012; Pinget et al., 2013; Riddle, Aronson, et al., 2013; Riddle, Forst, et al., 2013; Rosenstock et al.,…”
MethodYabe, D., Ambos, A., Cariou, B., Duvnjak, L. S., Evans, M., González-Gálvez, G., Lin, J., Nikonova, E. V., de Pablos-Velasco, P. L., Yale, J., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.018 · Cited by 18
Bonadonna, R. C., Blonde, L., Antsiferov, M. B., Berria, R., Gourdy, P., Hatunic, M., Mohan, V., & Horowitz, M. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2897 · Cited by 18
“Fasting plasma glucose also decreased, but to a lesser extent than PPG, as expected and consistent with previous studies.(15,16,23,24) Finally, although not assessed in the present study, it”
Result
Metadata
- Authors
- Ahrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R.
- Affiliations
- Lund University, Lund, Sweden
- Centro de Investigación Clínica del Pacifico, Acapulco, Mexico
- Sanofi (France) (FR)
- LMC Diabetes & Endocrinology (Canada) (CA)
- ORCID
- Aronson, Ronnie
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-08-13
- Volume
- 36
- Issue
- 9
- Pages
- 2543-2550
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3747937
- OpenAlex
- W2154433510
- Cited by
- 172
- References
- 27
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 5 · 2023: 9 · 2022: 4 · 2021: 4 · 2020: 5 · 2019: 8 · 2018: 9 · 2017: 23 · 2016: 24 · 2015: 17 · 2014: 29 · 2013: 17
- FWCI
- 22.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- lixisenatide, type 2 diabetes, metformin add-on therapy, inadequate glycemic control, HbA1c reduction, postprandial blood glucose, fasting blood glucose, body weight, nausea and vomiting, GLP-1 receptor agonists, injection timing, GIP/GLP-1 receptor agonist
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.